Niagen Bioscience Inc beat EPS estimates 100% of the time across 3 reported quarters (3 beats, 0 misses), averaging +22.2% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | $0.01 | $0.01 | +0.0% | Beat | |
| Q1 FY26 | $0.06 | $0.07 | +16.7% | Beat | Q1 FY26 call |
| Q4 FY25 | $0.02 | $0.03 | +50.0% | Beat |
Back to NAGE overview · NAGE holders · NAGE KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.